Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors.

Yoshida A, Bu Y, Qie S, Wrangle J, Camp ER, Hazard ES, Hardiman G, de Leeuw R, Knudsen KE, Diehl JA.

Sci Adv. 2019 Sep 18;5(9):eaax6352. doi: 10.1126/sciadv.aax6352. eCollection 2019 Sep.

2.

Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy.

Bowers JS, Bailey SR, Rubinstein MP, Paulos CM, Camp ER.

Oncol Rev. 2019 Aug 1;13(2):430. doi: 10.4081/oncol.2019.430. eCollection 2019 Jul 22.

3.

miR-145 Antagonizes SNAI1-Mediated Stemness and Radiation Resistance in Colorectal Cancer.

Zhu Y, Wang C, Becker SA, Hurst K, Nogueira LM, Findlay VJ, Camp ER.

Mol Ther. 2018 Mar 7;26(3):744-754. doi: 10.1016/j.ymthe.2017.12.023. Epub 2018 Jan 4.

4.

Abdominal Splenosis Mimicking Carcinomatosis in a Patient with Acute Appendicitis.

Schrank YM, George V, Camp ER.

Am Surg. 2017 Dec 1;83(12):e490-492. No abstract available.

PMID:
29336746
5.

The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.

Riley JM, Cross AW, Paulos CM, Rubinstein MP, Wrangle J, Camp ER.

Cancer. 2018 Apr 15;124(8):1650-1659. doi: 10.1002/cncr.31214. Epub 2018 Jan 9. Review.

6.

Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.

Liu D, Li G, Avella DM, Kimchi ET, Kaifi JT, Rubinstein MP, Camp ER, Rockey DC, Schell TD, Staveley-O'Carroll KF.

Oncoimmunology. 2017 Sep 21;7(1):e1372079. doi: 10.1080/2162402X.2017.1372079. eCollection 2017.

7.

Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer.

Camp ER, Patterson LD, Kester M, Voelkel-Johnson C.

Cancer Biol Ther. 2017 Sep 2;18(9):640-650. doi: 10.1080/15384047.2017.1345396. Epub 2017 Jul 7. Review.

8.

The impact of metabolic syndrome on outcome and response to neoadjuvant chemoradiation in locally advanced rectal cancer patients.

Anderson BJ, Wahlquist AE, Hill EG, Marshall DT, Kimchi ET, Staveley O'Carroll KF, Camp ER.

Int J Surg. 2016 Sep;33 Pt A:8-12. doi: 10.1016/j.ijsu.2016.07.011. Epub 2016 Jul 16.

9.

Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma.

Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS.

Cancer. 2016 May 1;122(9):1349-69. doi: 10.1002/cncr.29692. Epub 2016 Jan 22. Review.

10.

The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells.

Little EC, Camp ER, Wang C, Watson PM, Watson DK, Cole DJ.

Oncogenesis. 2016 Jan 11;5:e182. doi: 10.1038/oncsis.2015.45.

11.

Central Pancreatectomy with Pancreaticogastrostomy for the Treatment of a Solid-pseudopapillary Neoplasm.

Dowden JE, Kimchi ET, Camp ER, Morgan KA, Adams DB, Staveley-O'Carroll KF.

Am Surg. 2015 Nov;81(11):E383-4. No abstract available.

PMID:
26672573
12.

Ampullary Gangliocytic Paraganglioma with Lymph Node Metastasis.

Dowden JE, Staveley-O'Carroll KF, Kimchi ET, Camp ER, Morgan KA, Adams DB.

Am Surg. 2015 Nov;81(11):E359-60. No abstract available.

PMID:
26672564
13.

CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice.

Camp ER, Ellis LM.

Clin Cancer Res. 2015 Aug 15;21(16):3578-80. doi: 10.1158/1078-0432.CCR-14-2900.

14.

Application of an Advanced Image-Based Virtual Monoenergetic Reconstruction of Dual Source Dual-Energy CT Data at Low keV Increases Image Quality for Routine Pancreas Imaging.

Hardie AD, Picard MM, Camp ER, Perry JD, Suranyi P, De Cecco CN, Schoepf UJ, Wichmann JL.

J Comput Assist Tomogr. 2015 Sep-Oct;39(5):716-20. doi: 10.1097/RCT.0000000000000276.

PMID:
26196343
15.

The impact of surgical diversion before neoadjuvant therapy for rectal cancer.

Anderson BJ, Hill EG, Sweeney RE, Wahlquist AE, Marshall DT, Staveley O'Carroll KF, Cole DJ, Camp ER.

Am Surg. 2015 May;81(5):444-9.

16.

SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression.

Findlay VJ, Wang C, Nogueira LM, Hurst K, Quirk D, Ethier SP, Staveley O'Carroll KF, Watson DK, Camp ER.

Mol Cancer Ther. 2014 Nov;13(11):2713-26. doi: 10.1158/1535-7163.MCT-14-0207. Epub 2014 Sep 23.

17.

Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer.

Findlay VJ, Wang C, Watson DK, Camp ER.

Cancer Gene Ther. 2014 May;21(5):181-7. doi: 10.1038/cgt.2014.15. Epub 2014 May 2. Review.

18.

Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.

Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ, Romagnuolo J, Orwat KP, Marshall DT.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):837-44. doi: 10.1016/j.ijrobp.2013.12.030.

19.

The Diagnostic Significance of a Mucocele of the Appendix.

Craig DH, Ruddy JM, Pullatt RC, Hardie AD, Camp ER.

J S C Med Assoc. 2014 Mar-Apr;110(1):12-3.

PMID:
27125005
20.

Sentinel lymph node status in Merkel cell carcinoma of the head and neck: not a predictor of survival.

Fritsch VA, Camp ER, Lentsch EJ.

Head Neck. 2014 Apr;36(4):571-9. doi: 10.1002/hed.23334. Epub 2014 Jan 20.

PMID:
24446426
21.

Slug expression inhibits calcitriol-mediated sensitivity to radiation in colorectal cancer.

Findlay VJ, Moretz RE, Wang C, Vaena SG, Bandurraga SG, Ashenafi M, Marshall DT, Watson DK, Camp ER.

Mol Carcinog. 2014 Feb;53 Suppl 1:E130-9. doi: 10.1002/mc.22054. Epub 2013 Aug 31.

22.

MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer.

Guo QJ, Mills JN, Bandurraga SG, Nogueira LM, Mason NJ, Camp ER, Larue AC, Turner DP, Findlay VJ.

Breast Cancer Res. 2013;15(4):R70.

23.

The impact of lymph node disease in extremity soft-tissue sarcomas: a population-based analysis.

Johannesmeyer D, Smith V, Cole DJ, Esnaola NF, Camp ER.

Am J Surg. 2013 Sep;206(3):289-95. doi: 10.1016/j.amjsurg.2012.10.043. Epub 2013 Jun 24.

PMID:
23806824
24.

Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.

Camp ER, Wang C, Little EC, Watson PM, Pirollo KF, Rait A, Cole DJ, Chang EH, Watson DK.

Cancer Gene Ther. 2013 Apr;20(4):222-8. doi: 10.1038/cgt.2013.9. Epub 2013 Mar 8.

25.

Pneumatosis intestinalis after open jejunostomy tube placement.

Selander C, Pullatt R, Esnaola N, Camp ER.

Am Surg. 2013 Feb;79(2):E73-5. No abstract available.

PMID:
23336639
26.

Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients.

Yang Y, Mauldin PD, Ebeling M, Hulsey TC, Liu B, Thomas MB, Camp ER, Esnaola NF.

Cancer. 2013 Apr 15;119(8):1512-20. doi: 10.1002/cncr.27923. Epub 2012 Dec 20.

27.

The role of sentinel lymph node biopsy in select sarcoma patients: a meta-analysis.

Wright S, Armeson K, Hill EG, Streck C, Leddy L, Cole D, Esnaola N, Camp ER.

Am J Surg. 2012 Oct;204(4):428-33. doi: 10.1016/j.amjsurg.2011.12.019. Epub 2012 May 11.

PMID:
22578407
28.

Merkel cell carcinoma: identification of prognostic factors unique to tumors located in the head and neck based on analysis of SEER data.

Smith VA, Camp ER, Lentsch EJ.

Laryngoscope. 2012 Jun;122(6):1283-90. doi: 10.1002/lary.23222. Epub 2012 Apr 20.

PMID:
22522673
29.

Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer.

Little EC, Wang C, Watson PM, Watson DK, Cole DJ, Camp ER.

J Surg Res. 2012 Aug;176(2):359-66. doi: 10.1016/j.jss.2011.10.025. Epub 2011 Nov 10.

30.

Slug expression enhances tumor formation in a noninvasive rectal cancer model.

Camp ER, Findlay VJ, Vaena SG, Walsh J, Lewin DN, Turner DP, Watson DK.

J Surg Res. 2011 Sep;170(1):56-63. doi: 10.1016/j.jss.2011.02.012. Epub 2011 Mar 23.

31.

Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells.

Fan F, Gray MJ, Dallas NA, Yang AD, Van Buren G 2nd, Camp ER, Ellis LM.

Mol Cancer Ther. 2008 Sep;7(9):3064-70. doi: 10.1158/1535-7163.MCT-08-0615.

32.

Management of bevacizumab-associated bowel perforation: a case series and review of the literature.

Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN.

Ann Oncol. 2008 Mar;19(3):577-82. Epub 2007 Nov 16. Review.

PMID:
18024857
33.

The development and characterization of a human midgut carcinoid cell line.

Van Buren G 2nd, Rashid A, Yang AD, Abdalla EK, Gray MJ, Liu W, Somcio R, Fan F, Camp ER, Yao JC, Ellis LM.

Clin Cancer Res. 2007 Aug 15;13(16):4704-12.

34.

Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.

Bauer TW, Fan F, Liu W, Camp ER, Yang A, Somcio RJ, Bucana CD, Singh R, Ellis LM.

Ann Surg Oncol. 2007 Oct;14(10):2838-46. Epub 2007 Jul 26.

PMID:
17653802
35.

Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.

Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM.

Cancer. 2007 Mar 15;109(6):1030-9.

36.

The role of nitric oxide in mediating tumour blood flow.

Van Buren G 2nd, Camp ER, Yang AD, Gray MJ, Fan F, Somcio R, Ellis LM.

Expert Opin Ther Targets. 2006 Oct;10(5):689-701. Review.

PMID:
16981826
37.

Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.

Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4147-53.

38.
39.

Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.

Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, Somcio R, Bauer TW, Wu Y, Hicklin DJ, Ellis LM.

Cancer Res. 2006 Jan 1;66(1):46-51.

40.

Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB.

Li J, Minnich DJ, Camp ER, Brank A, Mackay SL, Hochwald SN.

J Surg Res. 2006 May;132(1):112-20. Epub 2005 Dec 9.

PMID:
16337965
41.

Minimizing local recurrence after breast conserving therapy using intraoperative shaved margins to determine pathologic tumor clearance.

Camp ER, McAuliffe PF, Gilroy JS, Morris CG, Lind DS, Mendenhall NP, Copeland EM 3rd.

J Am Coll Surg. 2005 Dec;201(6):855-61. Epub 2005 Sep 23.

PMID:
16310688
42.

Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.

Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM.

Cancer Res. 2005 Sep 1;65(17):7775-81.

43.

RON, a tyrosine kinase receptor involved in tumor progression and metastasis.

Camp ER, Liu W, Fan F, Yang A, Somcio R, Ellis LM.

Ann Surg Oncol. 2005 Apr;12(4):273-81. Epub 2005 Mar 15. Review.

PMID:
15827676
44.

Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy.

Yang AD, Bauer TW, Camp ER, Somcio R, Liu W, Fan F, Ellis LM.

Cancer. 2005 Apr 15;103(8):1561-70. Review.

45.

Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.

Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM.

Clin Cancer Res. 2005 Jan 1;11(1):397-405. Review.

46.

FAP with concurrent duodenal adenomatous polyposis and carcinoid tumor.

Camp ER, Hochwald SN, Liu C.

J Surg Oncol. 2004 Sep 15;87(4):187-90.

PMID:
15334634
47.

Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer.

Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, MacKay SL, Hochwald SN.

J Am Coll Surg. 2004 Aug;199(2):249-58.

PMID:
15275881
48.

Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer.

Voboril R, Hochwald SN, Li J, Brank A, Weberova J, Wessels F, Moldawer LL, Camp ER, MacKay SL.

J Surg Res. 2004 Aug;120(2):178-88.

PMID:
15234211
49.

The hottest sentinel lymph node is not always the positive node.

Camp ER, Cendan JC, Feezor R, Lind DS, Wilkinson E, Copeland EM.

Am Surg. 2004 Jun;70(6):475-8; discussion 478.

PMID:
15212397
50.

Blind Whipple resections for periampullary and pancreatic lesions.

Camp ER, Vogel SB.

Am Surg. 2004 Jan;70(1):6-10; discussion 11-2.

PMID:
14964538

Supplemental Content

Support Center